Compound Detail
CHEMBL4298200
LIFILEUCEL 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL4298200 |
| Name | LIFILEUCEL |
| Phase | Approved |
| Structure Type | NONE |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
6
Known Names
12
Indications
1
Mechanisms
Drug Information
| Molecule Type | Cell |
| First Approval | 2024 |
| Availability | Unknown |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Somatic cell supplemental therapy | - | - | ✓ | ✓ |
Indications
Melanoma Melanoma Melanoma Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Squamous Cell Endometrial Neoplasms Uterine Cervical Neoplasms Uterine Cervical Neoplasms Liver Neoplasms Mesothelioma Neoplasms
ATC Classification
L01XL11
lifileucel
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
Drug Warnings
Black Box Warning
General Warning
Data from ChEMBL 36 via Core Engine